statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sol-Gel Announces Executive Changes Amid Growth

Sol-Gel Technologies (SLGL) has released an update. Sol-Gel Technologies, a dermatology company known for its innovative skin treatments and FDA-ap...

Sol-Gel Technologies Announces Leadership Changes

Sol-Gel Technologies (SLGL) has released an update. Sol-Gel Technologies Ltd., an innovative dermatology company, announced a management realignmen...

Sol-Gel Technologies collaboration partner first-to-file ANDA generic to Zoryve

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve  Cream

Patent challenge initiated by Arcutis BiotherapeuticsNESS ZIONA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company pioneering treatments...

Sol-Gel Technologies reports 2023 EPS ($1.01) vs. (65c) last year

Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments

An ongoing phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened; Results are expected by the end of 2025 Sol-Gel maintains a cash runway into the second half of 2025...

Sol-Gel Technologies: Q4 Earnings Insights

Sol-Gel Technologies Ltd. operates as a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN, and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.

Sol-Gel Technologies Ltd

Volume	1.45M
52-Wk High	$3.92
52-Wk Low	$0.417

SLGL Sol-Gel Technologies Ltd

About

Feed

News

Sentiment

Earnings

Fundamentals